|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM159081211 |
| 003 |
DE-627 |
| 005 |
20231223083430.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0530.xml
|
| 035 |
|
|
|a (DE-627)NLM159081211
|
| 035 |
|
|
|a (NLM)16303334
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Crosby, Michelle B
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Inflammatory modulation of PPAR gamma expression and activity
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2006
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Nitric oxide (NO) production increases with age in the lupus-prone MRL/lpr mouse, paralleling disease activity. One mechanism for excess NO production in MRL/lpr mice may be a defect in down-regulatory mechanisms of the iNOS pathway. A potential modulator of NO is the nuclear hormone receptor peroxisome proliferation activated receptor gamma (PPARgamma). We demonstrate that renal PPARgamma protein expression was altered as disease progressed in MRL/lpr mice, which paralleled increased iNOS protein expression. Additionally, MRL/lpr-derived primary mesangial cells expressed less PPARgamma than BALB/c mesangial cells and produced more NO in response to LPS and IFNgamma. Furthermore, PPARgamma activity was reduced in mesangial cells following exposure to inflammatory mediators. This activity was restored with the addition of a NOS enzyme inhibitor. These results indicate that the activation of inflammatory pathways may lead to reduced activity and expression of PPARgamma, further exacerbating the disease state
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
| 650 |
|
7 |
|a Inflammation Mediators
|2 NLM
|
| 650 |
|
7 |
|a PPAR gamma
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide
|2 NLM
|
| 650 |
|
7 |
|a 31C4KY9ESH
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide Synthase Type II
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 650 |
|
7 |
|a Nos2 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 700 |
1 |
|
|a Zhang, John
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nowling, Tamara M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Svenson, John L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nicol, Christopher J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gonzalez, Frank J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gilkeson, Gary S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 118(2006), 2-3 vom: 15. Feb., Seite 276-83
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:118
|g year:2006
|g number:2-3
|g day:15
|g month:02
|g pages:276-83
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 118
|j 2006
|e 2-3
|b 15
|c 02
|h 276-83
|